Chugai Pharmaceutical Co., Ltd.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$16.6M
Doctors Paid
236
Transactions
2,792
2024 Total
$3.2M
Payment Breakdown by Category
Research$14.2M (85.1%)
Consulting$1.2M (7.5%)
Travel$884,957 (5.3%)
Royalty/License$330,000 (2.0%)
Food & Beverage$20,783 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14.2M | 1,935 | 85.1% |
| Consulting Fee | $1.2M | 432 | 7.5% |
| Travel and Lodging | $884,957 | 247 | 5.3% |
| Royalty or License | $330,000 | 15 | 2.0% |
| Food and Beverage | $20,783 | 162 | 0.1% |
| Education | $117.70 | 1 | 0.0% |
Payments by Type
Research
$14.2M
1,935 transactions
General
$2.5M
857 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD | $2.0M | 1 | 385 |
| A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | $2.0M | 0 | 202 |
| A Study of ERY974 in Patient With Advanced Solid Tumors | $1.7M | 0 | 132 |
| A PHASE1 STUDY TO EXPLORE THE SAFETY OF EOS789 IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERPHOSPHATEMIA ON HEMODIALYSIS | $1.4M | 0 | 13 |
| A PHASE I, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND COHORT EXPANSION STUDY OF SPYK04 AS MONOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | $1.2M | 0 | 95 |
| A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors | $1.1M | 0 | 102 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 as Monotherapy in Patients With Neuromyelitis Optica NMO and Neuromyelitis Optica Spectrum Disorder NMOSD | $649,743 | 0 | 125 |
| PRECLINICAL01252018 | $500,000 | 0 | 1 |
| A PHASE I OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY, EFFICACY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SAIL66 IN PATIENTS WITH CLDN6-POSITIVE LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | $499,589 | 0 | 128 |
| A PHASE Ia/Ib OPEN LABEL, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF ROSE12 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-TUMOR AGENTS IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | $468,816 | 0 | 118 |
| A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 GPC3CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors | $277,498 | 0 | 15 |
| PRE-CLINICAL01252019 | $250,000 | 0 | 1 |
| A Randomized, Double-Blind, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PCO371 in Patients with Hypoparathyroidism | $212,513 | 0 | 11 |
| A RANDOMIZED, DOUBLE-BLIND, MULTIPLE ASCENDING ORAL DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PCO371 IN PATIENTS WITH HYPOPARATHYROIDISM | $190,328 | 0 | 21 |
| A Phase 2 Study of CIM331 for Atopic Dermatitis Patients | $187,272 | 0 | 38 |
| A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS, AND BIOMARKERS OF DONQ52 IN CELIAC DISEASE PATIENTS | $134,270 | 0 | 10 |
| A PHASE 1 OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | $113,488 | 0 | 14 |
| PRE-CLINICAL06052017 | $90,246 | 0 | 1 |
| PRE-CLINICAL07062020 | $81,531 | 0 | 1 |
| Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD | $78,803 | 1 | 23 |
| OK432 IN THE TREATMENT OF LYMPHATIC MALFORMATIONS | $78,268 | 0 | 2 |
| AN EARLY FEASIBILITY STUDY TO EXPLORE A NOVEL OBJECTIVE PAIN MEASUREMENT USING A WEARABLE BIOSENSOR AND A NOVEL MOBILE PLATFORM IN PATIENTS WITH ENDOMETRIOSIS OPINE | $74,768 | 0 | 6 |
| PRE-CLINICAL7052017 | $52,585 | 0 | 2 |
| PRE-CLINICAL1162017 | $42,302 | 0 | 1 |
| A PHASE 1, OPEN LABEL DOSE-ESCALATION AND COHORT EXPANSION STUDY OF LUNA18 MONOTHERAPY IN AND COMBINATION THERAPY IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS | $36,350 | 0 | 3 |
| PRE-CLINICAL09152017 | $25,000 | 0 | 1 |
| A Multicenter, Randomized, Addition to Baseline Treatment, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Satralizumab SA237 in Patients With Neuromyelitis Optica NMO and NMO Spectrum Disorder NMOSD | $23,435 | 0 | 8 |
| PRE-CLINICAL04052017 | $15,000 | 0 | 1 |
| PRECLINICAL01152018 | $13,607 | 0 | 1 |
| A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY | $13,487 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2023 |
|---|---|---|---|---|
| Dr. Hope Rugo, Md, MD | Internal Medicine | San Francisco, CA | $20,078 | $0 |
| Dr. Ahmed Kaseb, Md, MD | Medical Oncology | Detroit, MI | $20,021 | $0 |
| Dr. Kieron Dunleavy, Md, MD | Hematology | Washington, DC | $19,857 | $0 |
| Joel Kopple, M.d, M.D | Nephrology | Torrance, CA | $19,801 | $0 |
| Mark Rosenberg, Md, MD | Internal Medicine | Minneapolis, MN | $19,470 | $0 |
| John Wagner, Md, MD | Pediatrics | Minneapolis, MN | $19,055 | $0 |
| Shirish Gadgeel, Md, MD | Internal Medicine | Detroit, MI | $18,782 | $0 |
| Dr. Dilraj Grewal, Md, MD | Ophthalmology | Chicago, IL | $18,767 | $0 |
| Anil Sood, M.d, M.D | Gynecologic Oncology | Houston, TX | $18,670 | $0 |
| Edmund Kopetz, M.d, M.D | Medical Oncology | Houston, TX | $18,621 | $0 |
| Anisha Patel, M.d, M.D | Dermatopathology | Houston, TX | $18,565 | $0 |
| Dr. Jeffrey Meyerhardt, Md Mph, MD MPH | Medical Oncology | Boston, MA | $18,486 | $0 |
| Magalis Llovet, Md, MD | Family Medicine | Grand Rapids, MI | $18,349 | $0 |
| Shumei Kato, M.b, M.B | Internal Medicine | Houston, TX | $17,909 | $0 |
| Sandra Swain, M.d, M.D | Hematology & Oncology | Bethesda, MD | $17,611 | $0 |
| Dr. David Hyman, Md, MD | Medical Oncology | New York, NY | $17,604 | $0 |
| Rajiv Saran, Mb, Bs, MB, BS | Internal Medicine | Ann Arbor, MI | $17,311 | $0 |
| Razelle Kurzrock, M.d, M.D | Hematology & Oncology | Milwaukee, WI | $17,303 | $0 |
| John Stone, M.d, M.D | Internal Medicine | Boston, MA | $17,259 | $0 |
| Dr. Pravin Dugel | Ophthalmology | Phoenix, AZ | $16,813 | $0 |
| Mitchell Horwitz | Hematology & Oncology | Durham, NC | $16,578 | $0 |
| Jean Vauthey, M.d, M.D | Surgical Oncology | Houston, TX | $16,403 | $0 |
| Prabir Roy-Chaudhury, M.d, M.D | Internal Medicine | Cincinnati, OH | $16,182 | $0 |
| Ken Young, Md, MD | Hematology | Houston, TX | $15,681 | $0 |
| David Ellison, Md, MD | Nephrology | Portland, OR | $15,553 | $0 |
About Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. has made $16.6M in payments to 236 healthcare providers, recorded across 2,792 transactions in the CMS Open Payments database. In 2024, the company paid $3.2M. The top product by payment volume is Non-Covered Product ($6.7M).
Payments were distributed across 47 medical specialties. The top specialty by payment amount is Internal Medicine ($440,610 to 44 doctors).
Payment categories include: Food & Beverage ($20,783), Consulting ($1.2M), Research ($14.2M), Travel & Lodging ($884,957), Royalties ($330,000).
Chugai Pharmaceutical Co., Ltd. is associated with 1 products in the CMS Open Payments database.